⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

Official Title: A Disease Registry for Patients With Tenosynovial Giant Cell Tumors (TGCT), Also Known as Pigmented Villonodular Synovitis (PVNS) and Giant Cell Tumor of the Tendon Sheath (GCT-TS)

Study ID: NCT02948088

Interventions

Study Description

Brief Summary: TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT (d-TGCT), the burden of d-TGCT for patients (including pain, joint stiffness, swelling, reduced mobility and quality of life) or the economic impact of d-TGCT. This study aims to collect data by an observational disease registry involving no intervention to the patient or changes to investigators treatment decisions.

Detailed Description: GCT is a rare, benign, but potentially locally aggressive and recurrent disease. Treatment pattern and treatment initiation, continuation or changes are solely at the discretion of the physician and the patient. There will be no attempt to influence the prescribing patterns of any individual treating physician. All medication will be prescribed in the usual standard of care and will not be provided by the study sponsor. Participation in the study will in no way influence payment or reimbursement for any treatment received by patients during the study. It is the responsibility of the investigator and his study staff to enter all relevant patient data required for this registry in the electronic Case Report Form (eCRF) and in the patients' medical records. Approximately 15 sites from up to 6 European Countries (France, Germany, Italy, The Netherlands, Spain and United Kingdom) and 4 sites from the US are planned to participate. The sites will be specialized sites that treat d-TGCT regularly.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

University of California San Francisco, San Francisco, California, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Medizinische Universität Graz, Graz, , Austria

CHU Nantes, Nantes, , France

Westdeutsches Tumorzentrum, Essen, , Germany

Istituto Ortopedico Rizzoli, Bologna, , Italy

Istituto Nazionale Tumori-Foundazione IRCCS, Milano, , Italy

Leiden University Medical Center, Leiden, , Netherlands

Radboud universitair medisch centrum, Nijmegen, , Netherlands

Hospital Sant Pau, Barcelona, , Spain

Hospital Universitario Virgen del Rocio, Sevilla, , Spain

The Royal Marsden Hospital, London, , United Kingdom

Nuffield Orthopaedic Centre, Oxford, , United Kingdom

Contact Details

Name: Global Clinical Leader

Affiliation: Daiichi Sankyo

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: